Search clinical trials for: JNJ-39439335

Total 1086 results

Janssen Research & Development, LLC

Withdrawn

A Study of the Clinical Activity and Safety of JNJ-64041809, a Live Attenuated Listeria Monocytogenes Immunotherapy, in Combination With Apalutamide Versus Apalutamide in Subjects With Metastatic Castration-resistant Prostate Cancer

Prostatic Neoplasms, Castration-Resistant

United States
Janssen Research & Development, LLC

Completed

To Assess the Pharmacokinetics and Safety of Single Doses of JNJ-54452840 in Healthy Japanese and Caucasian Participants

Healthy

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

JNJ-41443532 Sex, Race, and Age Pharmacokinetic (PK) Study

Healthy

United States
Janssen R&D Ireland

Completed

A Study in Healthy Participants Investigating the Safety, Tolerability and Plasma Pharmacokinetics (PK) of Single Oral Doses of JNJ-47910382

Hepatitis C Virus Infection

Germany
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of the Effects of JNJ-26489112 on the Photic Induced Paroxysmal Electroencephalogram (EEG) Response in Patients With Photosensitive Epilepsy

Photosensitive Epilepsy
Janssen Research & Development, LLC

Completed

A Study to Assess the Relative Bioavailability of JNJ64041575 Administered as 2 Different New Concept Formulations (Oral Suspension and Tablet) Compared to Their Respective Current Formulations, and to Assess the Effect of Food on the Pharmacokinetics of the 2 New Concept Formulations

Healthy

Belgium
Janssen-Cilag International NV

Completed

A Study to Investigate P2X7 Receptor Occupancy by JNJ-54175446 With the Newly Developed P2X7 Receptor Positron Emission Tomography (PET) Tracer 18F-JNJ-64413739

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-42721458 in Healthy Male Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study to Investigate the Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of an Intravenous Solution of JNJ-39588146 or Placebo in Patients With Heart Failure

Heart Failure

Belgium, Germany, Poland, Romania
Janssen Pharmaceutical K.K.

Terminated

A Study of JNJ-75220795 in Japanese Participants

Fatty Liver

Japan
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Effect of Hepatic Impairment on JNJ-42847922 in Adult Participants

Healthy | Hepatic Impairment

Germany
Janssen Research & Development, LLC

Terminated

A Study Evaluating Participants With Moderately to Severely Active Crohn's Disease (PRISM)

Crohn Disease

United States, Italy, Ukraine, Poland, Germany, Russian Federation, Argentina
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-77242113 in Healthy Japanese and Chinese Participants

Healthy

Japan
Janssen Research & Development, LLC

Completed

A Study of JNJ-80202135 in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

No longer available

Pre-approval Access Single Patient Request for Teclistamab (JNJ-64007957)

Multiple Myeloma
Janssen Pharmaceutical K.K.
Janssen Research & Development, LLC

Terminated

A Study of JNJ-64530440 in Healthy Japanese Male Participants

Healthy

Japan
Janssen-Cilag International NV

Completed

A Study of Orally Administered Pimodivir in Adult Participants With Hepatic Impairment

Hepatic Impairment

Germany
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-63733657 in Healthy Japanese Participants

Healthy

Japan
Janssen Research & Development, LLC

Completed

An Effectiveness and Safety Study of Inhaled JNJ 49095397 (RV568) in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Chronic Obstructive Pulmonary Disease

United Kingdom, United States, Belgium, Germany, Romania, Canada, Netherlands, Russian Federation, Poland, Hungary, Czechia
Janssen Research & Development, LLC

Completed

A Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand [18F]JNJ-64511070

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of Single and Multiple Ascending Doses of JNJ-61393215 in Healthy Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Withdrawn

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-56022473 in Subjects With Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

Germany
Janssen Sciences Ireland UC

Completed

A Study to Investigate Safety, Tolerability, and Pharmacokinetics of JNJ 53718678 in Healthy Japanese Adult Participants

Healthy

United Kingdom
Janssen Research & Development, LLC

Completed

A Study in Healthy Participants to Evaluate the Effect of JNJ-54175446 on Amyloid Biomarkers and Cytokine Profiles in Cerebrospinal Fluid and Plasma

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study of JNJ-38518168 in Symptomatic Adult Participants With Uncontrolled, Persistent Asthma

Asthma

United States, France, United Kingdom, Germany, Israel, Canada
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study Evaluating Effects of Intranasal JNJ-17166864 on Symptoms of Allergic Rhinitis in Adults

Allergic Rhinitis

United States
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Pharmacokinetics (PK) and Pharmacodynamics (PD) Study of Single and Multiple Ascending Doses of JNJ-41443532 in Healthy Male Participants

Healthy

Belgium
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Pharmacokinetic Study to Characterize JNJ-39393406 in the Cerebrospinal Fluid of Healthy Volunteers

Healthy Volunteers
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of JNJ-38431055 in Volunteers With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2
Janssen Research & Development, LLC

Completed

Study to Separately Evaluate the Activity of Talacotuzumab (JNJ-56022473) or Daratumumab in Transfusion-Dependent Participants With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS) Who Are Relapsed or Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment

Myelodysplastic Syndromes

United States, Belgium, Italy, Spain, Netherlands, Russian Federation
Janssen Research & Development, LLC

Completed

A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493 in Patients With Advanced or Refractory Solid Tumors or Lymphoma

Neoplasms | Lymphoma | Adenocarcinoma | Esophagogastric Junction

Japan
Janssen Research & Development, LLC
Mayo Clinic

Recruiting

A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)

Relapsed or Refractory B Cell Non-Hodgkin Lymphoma

United States, Australia, Israel
Janssen Research & Development, LLC

Completed

A Study of Seltorexant in Participants With Probable Alzheimer's Disease

Alzheimer Disease

United States
Janssen Research & Development, LLC

Temporarily not available

Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA)

Warm Autoimmune Hemolytic Anemia
Janssen Research & Development, LLC

Completed

A Study of JNJ-70033093 (BMS-986177) in Healthy Chinese Adult Participants

Healthy

China
Janssen Research & Development, LLC

Terminated

A Study of Bermekimab for the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

Dermatitis, Atopic

United States, Argentina
Johnson & Johnson Pharmaceutical Research & Development...

Terminated

Effectiveness and Safety Study for JNJ-18054478 in Asthma Patients.

Asthma

United States, Costa Rica, India
Janssen Research & Development, LLC

Completed

A Study of Nipocalimab in Healthy Male and Female Participants

Healthy

Netherlands
Janssen Research & Development, LLC

Terminated

A Study of Rilematovir (JNJ-53718678) in Adult Outpatients With Respiratory Syncytial Virus (RSV) Infection (PRIMROSE)

Respiratory Syncytial Virus

United States, Germany, Italy, Ukraine, Spain, Sweden, Thailand, Argentina, Bulgaria, Japan, Poland, Canada, Hungary, South Africa
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-40411813 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Safety and Immunogenicity of Different Doses of ExPEC4V (JNJ-63871860) in Healthy Japanese Adult Participants

Healthy

Japan
Johnson & Johnson Pharmaceutical Research & Development...

Completed

A Study of Effect of Food on the Pharmacokinetics of a Single JNJ-39823277 (TPI-1062) Dose in Healthy Participants

Healthy

United States
Janssen Research & Development, LLC

Recruiting

A Study of the Combination of Talquetamab and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma (RedirecTT-1)

Multiple Myeloma

United States, Korea, Republic of, Canada, Israel, Spain, Japan, Australia
Alios Biopharma Inc.

Completed

A Study of Orally Administered JNJ-440 to Evaluate the Safety, Tolerability, and Pharmacokinetics After Single Ascending Doses Including Food Effect Evaluation; After Multi-Day Dosing in Healthy Participants; and After Multiple (Ascending) Doses in Participants With Chronic Hepatitis B

Chronic Hepatitis B

Korea, Republic of, Moldova, Republic of, New Zealand, Thailand, Ukraine
Janssen Sciences Ireland UC

Terminated

Effects of JNJ-53718678 in Adult and Adolescent Participants Who Had a Hematopoietic Stem Cell Transplantation and Who Are Infected With Respiratory Syncytial Virus (RSV) (FREESIA)

Respiratory Syncytial Virus Infections

United States, Belgium, Taiwan, Israel, Japan, Argentina, Malaysia, Korea, Republic of, Netherlands, Spain, Australia, Italy, Brazil, France, United Kingdom, Sweden, Bulgaria
Janssen Research & Development, LLC

Recruiting

A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Myasthenia Gravis

Myasthenia Gravis

United States, Japan, Netherlands, Poland
Janssen Research & Development, LLC

Completed

A Phase 1b Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of JNJ-64565111 in Participants With Type 2 Diabetes Mellitus

Diabetes Mellitus, Type 2

United States
Janssen Research & Development, LLC

Completed

A Study of JNJ-77474462 (Bermekimab) in Healthy Participants of Japanese Descent Following Administration of Single Ascending Subcutaneous Doses

Healthy

Australia
Janssen Research & Development, LLC
Bristol-Myers Squibb

Completed

A Study of JNJ-70033093 in Healthy Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Investigate the Whole Body Distribution and Radiation Dosimetry of the Positron Emission Tomography Ligand Fluoride-18 (18F)-JNJ-64326067 in Healthy Participants

Healthy

United States

3

Subscribe